The class of Rslcan18 Inhibitors, encompasses a wide array of chemical compounds designed to indirectly modulate the activity or expression of the protein encoded by the Rslcan18 gene. This indirect approach relies on influencing key signaling pathways and regulatory mechanisms within the cell that Rslcan18 might be part of or influence, including PI3K/AKT, MAPK/ERK, and mTOR pathways, as well as processes related to protein degradation and gene expression regulation.
By targeting these cellular pathways and processes, the inhibitors can affect the functional context within which Rslcan18 operates, thereby modulating its activity or regulatory mechanisms. For example, kinase inhibitors like Staurosporine and specific pathway inhibitors such as LY294002 for PI3K, U0126 and PD98059 for MEK, and Rapamycin for mTOR offer insights into the complex regulatory networks governing cellular function and the potential roles of Rslcan18 within these networks. Moreover, the inclusion of compounds affecting gene expression and protein stability, such as Trichostatin A for histone deacetylation and Bortezomib for proteasome-mediated protein degradation, highlights the multifaceted strategies through which cellular signaling and function can be modulated.
This approach underscores the potential of pharmacological interventions to explore and influence the function of proteins like Rslcan18, providing a framework for understanding the interplay between chemical compounds and biological processes. Through their action, the inhibitors classified within the Rslcan18 Inhibitors group not only illuminate the potential mechanisms regulating Rslcan18 but also offer a broader perspective on the modulation of cellular signaling pathways, protein activity, and gene expression. This conceptual exploration emphasizes the complexity of cellular regulation and the potential for indirect modulation of specific protein functions through targeted pharmacological interventions, highlighting the intricate web of interactions that govern cellular signaling, regulation, and the response to external stimuli.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
A broad-spectrum kinase inhibitor, can disrupt multiple signaling pathways potentially regulated by Rslcan18. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
Inhibits PI3K, potentially affecting PI3K/AKT signaling pathways and indirectly modulating Rslcan18's activity or regulation. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
p38 MAPK inhibitor, can influence stress response signaling pathways possibly connected to Rslcan18's function. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
MEK inhibitor, can affect MAPK/ERK signaling, potentially altering pathways that Rslcan18 may influence. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
Another MEK inhibitor, can modify MAPK/ERK signaling pathways and potentially impact Rslcan18's regulatory mechanisms. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
Inhibits JNK, potentially modulating stress and apoptosis pathways that could intersect with Rslcan18's role. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
mTOR inhibitor, affecting cell growth and proliferation pathways that Rslcan18 may be involved in. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
Histone deacetylase inhibitor, can change chromatin structure and gene expression, possibly affecting Rslcan18. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Proteasome inhibitor, could indirectly affect the degradation of proteins regulated by Rslcan18. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $62.00 $112.00 $214.00 $342.00 | 74 | |
EGFR tyrosine kinase inhibitor, could modulate signaling pathways potentially relevant to Rslcan18's role in cellular signaling. | ||||||